Boston, MA -- (ReleaseWire) -- 04/18/2014 -- The Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals.
Comprehensive directory of royalty financing deals since 2007
Royalty financing contract documents
Royalty financing agreement terms
Royalty financing agreement structure
Top royalty financing deals by value
Most active Royalty financing dealmakers
The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter royalty financing partnering deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
View Full Report Details and Table of Contents
This report provides comprehensive access to royalty and revenue financing deals as announced in the life sciences industry since 2007.
This report contains links to online copies of actual royalty financing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of royalty financing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in royalty financing dealmaking as well as a discussion on the merits and attributes of royalty financing dealmaking.
Chapter 3 provides an overview of the structure of royalty financing deal contracts. The chapter includes numerous case studies to enable understanding of royalty financing deals for royalty assets.
Chapter 4 provides a review of the leading royalty financing deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of royalty financing contract documents since 2007, including deal value, press release and contract document. The chapter is organized by company A-Z.
Companies Mentioned in this Report: Abbott, Actavis, Allergan, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Endo, Forest, Fresenius, Galderma, Gilead Sciences, GlaxoSmithKline, Grifols, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Lundbeck, Menarini, Merck & Co, Merck KGaA, Mitsubishi Tanabe, Mylan, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue, Ranbaxy, Roche, Sanofi, Servier, Shionogi, Shire, Stada, Takeda, Teva, UCB view, Valeant, Warner Chilcott
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Diagnostics Partnering Terms and Agreements
- Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
- Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics
- Personalized Medicine in Oncology Partnering Terms and Agreements
- Companion Diagnostics Partnering Terms & Agreements
- Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Personalized Medicine Partnering Terms and Agreements
- Drug Delivery Partnering Terms and Agreements